HCV NS5B Polymerase Inhibitors for Sustained Viral Load Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis C virus (HCV) infection, particularly those involving combinations of pegylated alpha-interferon and ribavirin, do not achieve sustained viral load reduction in a substantial fraction of patients, highlighting a need for more effective therapeutic options.
Innovation Solution
Development of specific compounds, such as those described by formula I, which demonstrate activity against the HCV NS5B protein, potentially used in conjunction with other anti-HCV agents like interferons or cyclosporin, to inhibit viral replication and protein function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pegylated alpha-interferon and ribavirin are used as combination therapy, then initial viral load reduction is achieved, but sustained viral load reduction is not achieved in a substantial fraction of patients
Solution Approach 1:
The patent introduces novel chemical compounds with modified molecular structures (formula I) that target specific viral proteins (NS5B polymerase, NS3 protease) to change the therapeutic parameters and achieve sustained viral load reduction
Solution Approach 2:
The invention combines existing effective agents (pegylated alpha-interferon, ribavirin) with new compound classes (NS5B polymerase inhibitors, NS3 protease inhibitors) to create composite therapy regimens that overcome treatment resistance
2Productivity
If current HCV therapy combinations are used, then some patients achieve viral load reduction, but a substantial fraction of patients do not have sustained reduction
Solution Approach 1:
The patent segments the HCV life cycle into multiple targets (NS5B polymerase, NS3 protease, NS4A cofactor) and develops compounds that specifically inhibit each component, allowing combination therapy that addresses multiple stages of viral replication simultaneously
Solution Approach 2:
The invention uses NS4A as a key intermediary target, developing compounds that disrupt the NS3-NS4A complex formation, thereby indirectly inhibiting multiple downstream proteolytic cleavages and viral protein processing
Data Source
AI summary
The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.